Roche's new sequencing platform points to Asia-Pacific genomics competition
Roche's AXELIOS 1 platform is moving into Asia-Pacific research conversations as institutions weigh next-generation sequencing tools.
Roche is bringing its AXELIOS 1 next-generation sequencing platform into more Asia-Pacific research conversations after its global launch in June 2026. In a 9 November announcement, the company pointed to early adoption in South Korea and planned AXELIOS Days in Sydney and Seoul, where laboratory leaders will see demonstrations and discuss research uses. The regional activity matters to institutions weighing how to expand genomics capacity without committing every project to the same run size or turnaround time.
AXELIOS 1 uses Roche's sequencing by expansion technology. Roche says it converts DNA or RNA information into synthetic molecules called Xpandomers, around 50 times longer than the starting fragments, so the sequence can be read through its sensor. The company describes the system as a single-molecule platform designed for both smaller, time-sensitive batches and larger studies.
Speed and scale in a laboratory workflow
Roche says sequencing runs can take approximately 15 minutes to four hours and that a four-hour run can generate at least 1.8 terabases. It also says the platform has the potential to return whole-genome sequencing results within the same day. Those are company-described capabilities and potential workflows; each laboratory still has to assess how sample preparation, analysis, throughput and cost fit its own work.
The practical appeal is flexibility. A research lab may have a small urgent project one day and a much larger study the next. Roche argues that its platform can handle both without waiting to fill a large batch. Its announcement also says library-preparation kits and an open-source bioinformatics suite tailored to the technology will be available. Compatibility with established tools, local support and the total cost of running the system will influence procurement decisions alongside instrument speed.
Asia-Pacific research context
Roche plans AXELIOS Days in Sydney on 9–10 November and Seoul on 12–13 November. These are demonstration and discussion events, not evidence of a region-wide rollout. For Southeast Asian research institutions, the relevant question is whether new platform choices can help them process studies of different scales and build local analysis capability. AXELIOS 1 is designated for research use and is not for diagnostic procedures. Adoption will depend on independent laboratory evaluation and the workflows researchers need to support.
